Medical/Pharmaceuticals News & Press Release Distribution

Transcenta Releases Phase I Clinical Data of TST001 in Combination with CAPOX as the First Line Treatment of Advanced and Metastatic G/GEJ Cancer at ASCO 2022

SUZHOU, China, June 2, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that clinical data for...

2022-06-02 08:08 2504

Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOT BIOPHARM Shares

SUZHOU, China, June 2, 2022 /PRNewswire/ -- On June 1, 2022, TOT BIOPHARM International Company Limited (TOT BIOPHARM, Stock code: 1875.HK) announced that the company entered into a Share Subscription Agreement with VIVO Suzhou Fund and Centerlab. Pursuant to the agreement, Vivo Suzhou Fund and C...

2022-06-02 08:00 5585

Concord Medical Announces Its Subsidiary's Application Filing for Potential Listing on The Stock Exchange of Hong Kong Limited

BEIJING, June 1, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensiv...

2022-06-02 04:15 2088

First AI to Refine Medical Coding by Exploring Therapeutic Data

SAN FRANCISCO, June 1, 2022 /PRNewswire/ -- Medical AI start-up Aesop Technology announced a new partnership that made their new product,DxPrime , available in the Olive Library . DxPrime provides physicians and ...

2022-06-02 01:22 2451

Harbour BioMed Reports the Latest Progress of Next-Generation Fully Human Heavy-chain Antibody HBM4003 with Unique Treg Depletion Mechanism

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 1, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, today announced the progress ...

2022-06-01 21:24 2048

Standigm Signs MOU with Merck Korea for AI drug Discovery Research

- Merck's retrosynthesis AI software SYNTHIA™ accelerates Standigm's synthesis capability SEOUL, South Korea, June 1, 2022 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, today announced the signing of a Memorandum of Und...

2022-06-01 21:00 2135

Standigm Signs MOU with Merck Korea for AI drug Discovery Research

Burning Rock Receives CE Mark for its OverC™ Multi-Cancer Detection Blood Test Kit

SHANGHAI, June 1, 2022 /PRNewswire/ -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock") announced that it has received CE marking for its OverC™ Multi-Cancer Detection Blood Test manufactured in both the US and China facilities (Identification Number: DE/CA20/01-IVD-Luxu...

2022-06-01 19:49 1571

Cambrex Acquires Leading EU Stability Storage Company Q1 Scientific

EAST RUTHERFORD, NJ, June 1, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced the acquisition of Q1 Scientific – a leading pr...

2022-06-01 18:00 1971

Cambrex Acquires Leading EU Stability Storage Company Q1 Scientific

PMB Announces EIT Health Supported FLASHKNiFE Consortium Towards the Clinical Application of FLASH Radiation Therapy

PEYNIER, France, June 1, 2022 /PRNewswire/ -- PMB announces the launch of the FLASHKNiFE Consortium, supported by the European Institute of Innovation & Technology for Health (EIT Health). This European public-private partnership aims at advancing radiation therapy by introducing a new radiothera...

2022-06-01 16:15 1974

PMB Announces EIT Health Supported FLASHKNiFE Consortium Towards the Clinical Application of FLASH Radiation Therapy

Tau-targeting Alzheimer's treatment, HMTM, moving toward regulatory submission based on initial data from TauRx's LUCIDITY trial

* LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer's based on published research * Safety profile is favourable and consistent with previous HMTM studies * TauRx will now pursue regulatory ...

2022-06-01 16:00 1684

AMGEN AND NSG BIOLABS ANNOUNCE GOLDEN TICKET TO BOOST SINGAPORE'S BIOTECH ECOSYSTEM

Amgen is the inaugural sponsor of the NSG Tomorrow Programme that aims to support innovation among biotech startups inSoutheast Asia SINGAPORE, June 1, 2022 /PRNewswire/ -- Amgen , a leading global biotechnology company, andNSG BioLabs , Singapore's l...

2022-06-01 10:00 2722

Antengene to Present Clinical Results of ATG-008 (Onatasertib) at the 2022 American Society of Clinical Oncology Annual Meeting

Poster will report data from the Phase I/II TORCH-2 Study that evaluates ATG-008 (onataseritb) and toripalimab in patients with advanced solid tumors TORCH-2 is the world's first clinical study evaluating the combination of a dual mTORC1/2 inhibitor and an anti-PD-1 monoclonal antibody SHANGHAI ...

2022-06-01 08:30 2246

Innovent Appoints Mr. Gary Zieziula as Independent Non-executive Director

SAN FRANCISCO and SUZHOU, China, June 1, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and ...

2022-06-01 08:00 2629

Innovent Appoints Mr. Gary Zieziula as Independent Non-executive Director

Kemin Food Technologies - Asia Introduces Antimicrobial Disinfectant Solutions KEEPER™ and OXINE™

Latest product lines address safety at the start by treating food, water and the preparation space for food SINGAPORE, June 1, 2022 /PRNewswire/ -- Kemin Industries, a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world w...

2022-06-01 08:00 2717

Avulux and CR Surfacing partner to make innovative migraine & light sensitivity lenses available through eye-care practitioners across Australia

Australians living with migraine can now come 'out of the dark' with Avulux migraine lenses DANDENONG SOUTH, Australia, June 1, 2022 /PRNewswire/ -- The world's first clinically proven lens for migraine and light sensitivity management is now available through eye-care practitioners inAustralia....

2022-06-01 05:00 2190

Avulux and CR Surfacing partner to make innovative migraine & light sensitivity lenses available through eye-care practitioners across Australia

CStone Pharmaceuticals Reports 2021 Annual Results and Recent Business Highlights

SUZHOU, China, June 1, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today reported 2021 full-year financial results a...

2022-06-01 00:35 5357

Toku Eyes, Developer of an AI Platform That Accurately Identifies Risk of Heart Attack Using an Eye Image, Expands to The US

With Toku Eyes' artificial intelligence platform, the eye is not only the window to the soul — it is now a window to the state of your health AUCKLAND, New Zealand, May 31, 2022 /PRNewswire/ -- Toku Eyes, the New Zealand -based developer of a multi-modal artificial intelligence platform for instan...

2022-06-01 00:00 2038

QureBio Ltd. to Showcase its Q-1802 Clinical Advances at 2022 ASCO Annual Meetings

SHANGHAI, May 31, 2022 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on bi-specific antibodies and other engineered bio-therapeutics for the treatment of cancer, inflammation, and other serious disorders, today announced that its Q-1802 clinical program was se...

2022-05-31 22:30 2743

QureBio Ltd. to Showcase its Q-1802 Clinical Advances at 2022 ASCO Annual Meetings

SHANGHAI, May 31, 2022 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on bi-specific antibodies and other engineered bio-therapeutics for the treatment of cancer, inflammation, and other serious disorders, today announced that its Q-1802 clinical program was se...

2022-05-31 22:30 1911

BIOMERICS ANNOUNCES EXPANSION INTO IRELAND

Expands High-Performance Balloon Design & Development Capabilities in Galway SALT LAKE CITY, May 31, 2022 /PRNewswire/ -- Biomerics, the leading vertically integrated medical device contract manufacturer serving the interventional device market, has today announced the opening of a 2,000 sq. f...

2022-05-31 22:05 3489